Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

consultant review.

Financial Results

The consolidated net loss for the year ended December 31, 2007 was $47.2 million or ($0.56) per share compared with a consolidated net loss of $40.9 million or ($0.62) per share for the previous year. The consolidated net loss for the fourth quarter ended December 31, 2007 was $11.7 million or ($0.13) per share compared with a consolidated net loss of $14.1 million or ($0.20) per share for the fourth quarter of the previous year.

Total consolidated expenses for the year ended December 31, 2007 were $48.0 million compared to $42.2 million for the previous year. Total consolidated expenses for the three months ended December 31, 2007 were $12.1 million compared to $14.4 million for the same quarter of the previous year.

Research and development expenses for the year ended December 31, 2007 totaled $38.9 million compared with $35.2 million in 2006. The increase was due primarily to the start up and initial enrollment of patients in the MAESTRO-02 follow-on trial, the full enrollment and continuation of the MINDSET-01 clinical trial and the start-up and commencement of enrolment of the MAESTRO-03 clinical trial. It is expected that research and development expenses will increase over the next two years as the current clinical trials for MBP8298; MAESTRO-01, MAESTRO-02, MAESTRO-03 and MINDSET-01, continue in Canada, Europe and the U.S.

Research and development expenses were $9.3 million for the fourth quarter ended December 31, 2007 compared to $12.5 million for the fourth quarter of the previous year. The reduction in expenses was the net result of reduced costs for the MAESTRO-01 trial, as more patients are completing or near completion of their two years on the trial, and a reduction in the number of batches of MBP8298 manufactured in the year, offset by start-up costs for the MAESTRO-02 and MAESTRO-03 trials.

General and administrative expenses were $7.5 million for the year ended December
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... JH Technologies announces the ... Irvine. JH Technologies, a leader in sales and ... an expanded partnership with Leica Microsystems into the Southern ... analysis solutions will be featured at the grand opening ... showroom facility is located within the JH Technologies office’s ...
(Date:9/17/2014)... PITTSBURGH , Sept. 17, 2014 ... maker of MD-Cu 29 antimicrobial copper, announces Gilmour ... points to the first EPA-registered antimicrobial solid touch surface ... copper is a reasonably priced surface that kills greater ... 2 hours of exposure. 1 ...
(Date:9/17/2014)... , 17 de septiembre de 2014 /PRNewswire/ ... principal proveedor mundial de soluciones logísticas avanzadas ... de la vida, anunció hoy la contratación ... global con sede en Rótterdam, Países Bajos, ... clientes Europa en rápido crecimiento. Según los ...
(Date:9/17/2014)... The Pistoia Alliance, a global not ... to innovation in life sciences R&D through pre-competitive ... as Executive Director Business Development North America, as ... , Carmen joins the Pistoia Alliance from Accelrys ... Accelrys, she managed various life sciences and material ...
Breaking Biology Technology:JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... Acid Isolation , Kit , , ... , of histologists and pathologists ... and making patient diagnoses. More than 400 million FFPE , ... these samples can be tied to clinical data. Using one simple ...
... Prevalence and Roles of ... than 200 miRNAs have been cloned , ... apparently regulates multiple genes, and miRNAs are thought to , ... predict mRNA target sites for miRNAs [2,3]. A ...
... , RNA later ... sample collection and during shipping. , Whether ... you can use this aqueous, non-toxic Tissue Collection:RNA , ... -20C. , ...
Cached Biology Technology:Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue 2Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue 3Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue 4Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 2Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 3Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 4Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 5Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 6Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 7Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 8Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 9Preserve Samples for RNA Expression Microarrays RNAlater Around the World 2Preserve Samples for RNA Expression Microarrays RNAlater Around the World 3Preserve Samples for RNA Expression Microarrays RNAlater Around the World 4Preserve Samples for RNA Expression Microarrays RNAlater Around the World 5
(Date:9/16/2014)... (September 17, 2014)The North American Menopause Society (NAMS) ... comprehensive care of midlife womenon everything from hot ... North American Menopause Society Recommendations for Clinical Care ... the Society,s journal Menopause . This is ... the care of midlife women freely available to ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... 10-km diameter chunk of rock hit the Yukatan peninsula near ... force of 100 teratons of TNT. It left a crater ... global earthquakes and volcanism are widely accepted to have wiped ... the mammals. But what happened to the plants on which ... from the University of Arizona reveals that the meteorite impact ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... born to obese mothers are at risk for iron ... a study to be presented Saturday, April 30, at ... In nonpregnant adults, obesity-related inflammation hinders the transport ... iron deficiency anemia. When a woman is pregnant, iron ...
... an August 2010 ban on federal funding of embryonic stem ... stem cells function and how they can be harnessed to ... ruling has been welcomed by the Obama Administration, which attempted ... top researchers in the field, including Arnold Kriegstein, MD, PhD, ...
... a groundbreaking new videojournal to complement the ... & Advanced Surgical Techniques has been ... ( http://www.liebertpub.com ). Videoscopy ( http://www.liebertpub.com/products/product.aspx?pid=390 ) ... of the latest techniques and technologies used ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: